[Immunotherapy and cancers: last news from the front (Asco 2015)].
Jean-Yves
JY
Nau
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002641:Chicago; D003226:Congresses as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D000074324:Ipilimumab; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D000077594:Nivolumab
D000911:Antibodies, Monoclonal; D000074324:Ipilimumab; D000077594:Nivolumab